Hospitalized elderly with at least one risk factor for Covid-19 disease Infections and Infestations
Conditions
Interventions
We retrospectively evaluated the efficacy and safety of treatment with molnupiravir, which we started oral administration within 24 hours after the onset of signs or symptoms in hospitalized elderly w
Sponsors
Fukushima Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Over 80 years of age 2. At least one risk factor of: age >60 years, active cancer, chronic kidney disease, chronic obstructive pulmonary disease, obesity defined by a body-mass index (the weight in kilograms divided by the square of the height in meters) =30, serious heart conditions (heart failure, coronary artery disease, or cardiomyopathies), diabetes mellitus, according to the guidance of Food and Drug Administration and World Health Organization (WHO)
Exclusion criteria
Exclusion criteria: 1. The use of dialysis 2. Estimated glomerular filtration rate of 30 ml/minute/1.73 m² or less 3. Pregnancy 4. Neutropenia (neutrophil count of <500 / ml) 5. Platelet count <100,000/microliter 6. Monoclonal antibodies 7. Remdesivir
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using patient records: Adverse events are measured by seeing patients, 7, 14, 21 and 28 days. 1. Nausea, vomiting, anaphylaxis, and disturbance are measured within 7 days. 2. Massive sputum, anorexia and hypoxia are within 14 days. 3. Feeling dizzy, headaches and diarrhea are within 21 days. 4. Inedia and melena are within 28 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured based on the results of the clinical diagnosis by the attending physician: 1. Efficacy at 7 days 2. Safety within 28 days | — |
Countries
Japan
Outcome results
None listed